These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23206263)

  • 61. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States.
    Nicholas J; Halpern R; Ziehn M; Peterson-Brandt J; Leszko M; Deshpande C
    J Med Econ; 2020 Aug; 23(8):885-893. PubMed ID: 32338098
    [No Abstract]   [Full Text] [Related]  

  • 63. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Managed care aspects of managing multiple sclerosis.
    Mathis AS
    Am J Manag Care; 2013 Feb; 19(2 Suppl):S28-34. PubMed ID: 23544718
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.
    Walter H; Sadeque-Iqbal F; Ulysse R; Castillo D; Fitzpatrick A; Singleton J
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):69-81. PubMed ID: 26571284
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interventions to support risk and benefit understanding of disease-modifying drugs in Multiple Sclerosis patients: A systematic review.
    Reen GK; Silber E; Langdon DW
    Patient Educ Couns; 2017 Jun; 100(6):1031-1048. PubMed ID: 28108125
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sodium channel blockers for neuroprotection in multiple sclerosis.
    Yang C; Hao Z; Zhang L; Zeng L; Wen J
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010422. PubMed ID: 26486929
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Early Relapsing Multiple Sclerosis.
    Jones DE
    Continuum (Minneap Minn); 2016 Jun; 22(3):744-60. PubMed ID: 27261680
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk evaluation and monitoring in multiple sclerosis therapeutics.
    Clanet MC; Wolinsky JS; Ashton RJ; Hartung HP; Reingold SC
    Mult Scler; 2014 Sep; 20(10):1306-11. PubMed ID: 24293456
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.
    Ryan R; Santesso N; Lowe D; Hill S; Grimshaw J; Prictor M; Kaufman C; Cowie G; Taylor M
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD007768. PubMed ID: 24777444
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
    Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
    Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Improving cost-effectiveness of and outcomes from drug therapy in patients with atrial fibrillation in managed care: role of the pharmacist.
    Johnson SG
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S19-25. PubMed ID: 19678723
    [TBL] [Abstract][Full Text] [Related]  

  • 76. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Azathioprine for multiple sclerosis.
    Casetta I; Iuliano G; Filippini G
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003982. PubMed ID: 17943809
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J; Kalinowska-Łyszczarz A
    J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.